Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1996 Sep;51(9):941–943. doi: 10.1136/thx.51.9.941

Adrenal suppression with inhaled budesonide and fluticasone propionate given by large volume spacer to asthmatic children.

D J Clark 1, R A Clark 1, B J Lipworth 1
PMCID: PMC472620  PMID: 8984708

Abstract

BACKGROUND: The aim of this study was to compare the systemic bioactivity of inhaled budesonide (B) and fluticasone propionate (F), each given by large volume spacer, on a microgram equivalent basis in asthmatic children. METHODS: Ten stable asthmatic children of mean age 11 years and forced expiratory volume in one second (FEV1) 81.6% predicted, who were receiving treatment with < or = 400 micrograms/day of inhaled corticosteroid, were studied in a placebo controlled single blind (investigator blind) randomised crossover design comparing single doses of inhaled budesonide and fluticasone propionate 400 micrograms, 800 micrograms, and 1250 micrograms. Doses were given at 20.00 hours with mouth rinsing and an overnight 12 hour urine sample was collected for estimation of free cortisol and creatinine excretion. RESULTS: The results of overnight 12 hour urinary cortisol output (nmol/12 hours) showed suppression with all doses of fluticasone propionate (as geometric means): F400 micrograms (11.99), F800 micrograms (6.49), F1250 micrograms (7.00) compared with placebo (24.43), whereas budesonide caused no suppression at any dose. A comparison of the drugs showed that there were differences at 800 micrograms and 1250 micrograms levels for urinary cortisol: B800 micrograms versus F800 micrograms (2.65-fold, 95% CI 1.26 to 5.58), B1250 micrograms versus F1250 micrograms (2.94-fold, 95% CI 1.67 to 5.15). The results for the cortisol/creatinine ratio were similar to that of urinary cortisol, with fluticasone causing suppression at all doses and with differences between the drugs at 800 micrograms and 1250 micrograms. CONCLUSIONS: Single doses of inhaled fluticasone produce greater systemic bioactivity than budesonide when given by large volume spacer on a microgram equivalent basis in asthmatic children. The systemic bioactivity of fluticasone, like budesonide, is due mainly to lung bioavailability.

Full text

PDF
941

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Clark D. J., Grove A., Cargill R. I., Lipworth B. J. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax. 1996 Mar;51(3):262–266. doi: 10.1136/thx.51.3.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Harding S. M. The human pharmacology of fluticasone propionate. Respir Med. 1990 Nov;84 (Suppl A):25–29. doi: 10.1016/s0954-6111(08)80004-2. [DOI] [PubMed] [Google Scholar]
  3. Högger P., Rohdewald P. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids. 1994 Oct;59(10):597–602. doi: 10.1016/0039-128x(94)90054-x. [DOI] [PubMed] [Google Scholar]
  4. Lipworth B. J. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax. 1995 Feb;50(2):105–110. doi: 10.1136/thx.50.2.105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Melchor R., Biddiscombe M. F., Mak V. H., Short M. D., Spiro S. G. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax. 1993 May;48(5):506–511. doi: 10.1136/thx.48.5.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Pedersen S., Steffensen G., Ekman I., Tönnesson M., Borgå O. Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol. 1987;31(5):579–582. doi: 10.1007/BF00606634. [DOI] [PubMed] [Google Scholar]
  7. Phillipps G. H. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med. 1990 Nov;84 (Suppl A):19–23. doi: 10.1016/s0954-6111(08)80003-0. [DOI] [PubMed] [Google Scholar]
  8. Ryrfeldt A., Andersson P., Edsbäcker S., Tönnesson M., Davies D., Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl. 1982;122:86–95. [PubMed] [Google Scholar]
  9. Thorsson L., Edsbäcker S., Conradson T. B. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J. 1994 Oct;7(10):1839–1844. doi: 10.1183/09031936.94.07101839. [DOI] [PubMed] [Google Scholar]
  10. Toogood J. H., Baskerville J., Jennings B., Lefcoe N. M., Johansson S. A. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis. 1984 May;129(5):723–729. doi: 10.1164/arrd.1984.129.5.723. [DOI] [PubMed] [Google Scholar]
  11. Wolthers O. D., Pedersen S. Measures of systemic activity of inhaled glucocorticosteroids in children: a comparison of urine cortisol excretion and knemometry. Respir Med. 1995 May;89(5):347–349. doi: 10.1016/0954-6111(95)90006-3. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES